Neurol. pro Praxi, 2003; 4: 204-207

Levetiracetam, klinické zkušenosti

MUDr. Jana Zárubová1, MUDr. Jiří Dolanský2
1 Neurologická klinika IPVZ, Fakultní Thomayerova nemocnice Praha
2 Centrum pro epileptologii a epileptochirurgii IPVZ a FTN, Praha-Krč

Keywords: levetiracetam, epilepsie, antiepileptika.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zárubová J, Dolanský J. Levetiracetam, klinické zkušenosti. Neurol. praxi. 2003;4(4):204-207.

Autoři podávají přehled klinických zkušeností s přídatnou léčbou farmakorezistentní epilepsie levetiracetamem u souboru 65 pacientů. Levetiracetam dlouhodobě užívalo 54 pacientů souboru, minimálně tři měsíce, maximálně 15 měsíců. V souboru bylo 63 % respondérů, tj. pacientů, u kterých došlo k redukci frekvence záchvatů o 50 % a více, 20 % pacientů celého souboru bylo po nasazení levetiracetamu bez záchvatů. U 11 pacientů (16,9 %) byl levetiracetam pro nedostatečnou účinnost a/nebo vedlejší účinky vysazen.

Download citation

References

  1. Cereghino JJ, Biton V, Abou-Khalil B, Dreifus F, Gauer LJ, Leppik I. Levetiracetam for partial seizures. Neurology 2000; 55: 236-242. Go to original source... Go to PubMed...
  2. Doležal T, Zárubová J. Levetiracetamum. Remedia 2002; 6: 370-374.
  3. French J, Edrich P, Frajer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001; 47: 77-90. Go to original source... Go to PubMed...
  4. Krakow K, Walker M, Otoul C, Sander JWAS. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772-1774. Go to original source... Go to PubMed...
  5. Shorvon SD, Löwenthal A, Janz D, Bidlem E, Loiseau P. Multicenter Double-blind, Randomized, Placebo-Controlled Trial of Levetiracetam as Add-On Therapy in Patients with Refractory Partial Seizures. Epilepsia 2000; 41 (9): 1179-1186. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.